Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment

Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors

(2021) Marcus Skribek et al.   EUROPEAN JOURNAL OF CANCER

The association between tumor mutational burden and prognosis is dependent on treatment context

(2021) Cristina Valero et al.   NATURE GENETICS

Role of Gut Microbiome in the Outcome of Cancer Immunotherapy

(2021) Junting Ma et al.   INTERNATIONAL JOURNAL OF CANCER

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

(2021) Deborah Blythe Doroshow et al.   Nature Reviews Clinical Oncology

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: Real world experience in Argentina

(2020) Claudio Martin et al.   Clinical Lung Cancer

Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

(2020) Fausto Petrelli et al.   Cancers

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

(2020) MARTIN SVATON et al.   ANTICANCER RESEARCH

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

(2020) Daniel Spakowicz et al.   BMC CANCER

The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade

(2020) Isobel S. Okoye et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study

(2020) Vitale Maria Giuseppa et al.   Clinical Genitourinary Cancer

Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal

(2020) Marie-Léa Gauci et al.   Clinics and Research in Hepatology and Gastroenterology

Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases

(2020) Takehiro Tozuka et al.   Thoracic Cancer

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

(2020) Barzin Y. Nabet et al.   CELL

Steroid Use Independently Predicts Poor Outcome In Patients With Advanced Nsclc And High Pd-L1 Expression Receiving First-Line Pembrolizumab Monotherapy

(2020) Giannis Mountzios et al.   Clinical Lung Cancer

Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor–induced gastroenterocolitis

(2020) Leah L. Thompson et al.   EUROPEAN JOURNAL OF CANCER

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%

(2020) Giulio Metro et al.   JOURNAL OF IMMUNOTHERAPY

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy

(2020) David J Pinato et al.   Journal for ImmunoTherapy of Cancer

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)

(2020) Andrea De Giglio et al.   Cancers

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

(2020) Mariona Riudavets et al.   Frontiers in Oncology

Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives

(2020) Daniele Marinelli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

(2020) Sebastiano Buti et al.   EUROPEAN JOURNAL OF CANCER

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

(2020) Bairavi Shankar et al.   JAMA Oncology

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure

(2020) Ranjan Pathak et al.   Cancers

Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

(2019) Lizza E.L. Hendriks et al.   Journal of Thoracic Oncology

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution

(2019) AMMAR SUKARI et al.   ANTICANCER RESEARCH

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)

(2019) Motohiro Tamiya et al.   INVESTIGATIONAL NEW DRUGS

Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications

(2019) Biagio Ricciuti et al.   JOURNAL OF CLINICAL ONCOLOGY

A Nationwide Survey of Japanese Palliative Care Physicians' Practice of Corticosteroid Treatment for Dyspnea in Patients With Cancer

(2019) Kozue Suzuki et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status

(2019) Yuichi Adachi et al.   Cancer Medicine

High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma

(2018) Alexander T. Faje et al.   CANCER

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies

(2018) Shetal A. Patel et al.   IMMUNITY

Brief report: Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab

(2018) Susan Combs Scott et al.   Journal of Thoracic Oncology

Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab

(2018) Coraline Dumenil et al.   PLoS One

Side effects of corticosteroids in patients with advanced cancer: a systematic review

(2018) Yutaka Hatano et al.   SUPPORTIVE CARE IN CANCER

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

(2018) Kathryn C. Arbour et al.   JOURNAL OF CLINICAL ONCOLOGY

Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system

(2018) Russell Maxwell et al.   OncoImmunology

Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management

(2017) Bernardo L. Rapoport   Frontiers in Pharmacology

Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy

(2015) Kailin Xing et al.   BMC IMMUNOLOGY

High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma

(2015) J. Zaragoza et al.   BRITISH JOURNAL OF DERMATOLOGY

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center

(2015) Douglas B. Johnson et al.   Cancer Immunology Research

How to obtain the confidence interval from a P value

(2011) D. G. Altman et al.   BMJ-British Medical Journal

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

(2009) J. Weber et al.   CLINICAL CANCER RESEARCH

Association between Metabolic Syndrome and Risk of Stroke: A Meta-Analysis of Cohort Studies

(2008) Wei Li et al.   CEREBROVASCULAR DISEASES